Immune Checkpoints: Therapeutic Targets for Pituitary Tumors. (17th August 2021)

• Record Type: Journal Article
• Authors: Nie, Ding; Xue, Yimeng; Fang, Qiuyue; Cheng, Jianhua; Li, Bin; Wang, Dawei; Li, Chuzhong; Gui, Songbai; Zhang, Yazhuo; Zhao, Peng
• Other Names: Zeng Xianwei Academic Editor.
• Is Part Of: Disease markers. Volume 2021(2021)
• Publication Date: 2021-08-17
• Subjects: Diagnosis -- Periodicals; Biochemical markers -- Periodicals; Pathology -- Periodicals; 616
• DOI: 10.1155/2021/5300381
• Languages: English
• ISSNs: 0278-0240

Abstract

Abstract : Pituitary tumors are the third most common intracranial tumors in adults. Treatment of refractory pituitary tumors is known to be difficult due to limited treatment options. As a promising therapeutic method, tumor immunotherapy has been applied in the treatment of many tumors, including pituitary tumors. Immune checkpoint blocking is one of the effective strategies to activate antitumor immunity. Immune checkpoints prevent tissue damage by regulating the immune response of peripheral tissues and participate in the maintenance of a normal immune environment. In the presence of a tumor, inhibition of T cell activity by tumor cells binding to immune checkpoints and their ligands is an important mechanism for tumor cells to escape immune injury. In this review, we summarize the latest findings of immune checkpoints and their potential as immunotherapeutic targets for pituitary tumors.